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Gaub, 2006). The information they gained from the pull-
ing could be used to supplement what could be learned
from diffraction data. Further, the combination of dif-
fraction data with single-molecule mechanics could be
used to learn more about the structural correlates of
the measured forces and distances in the molecular
mechanics curves of force versus distance.
One challenge for the future will be moving to ion
channels that cannot be crystallized, but are extremely
important for understanding human health, and learning
about them. Another direction for the future is moving
from single-molecule mechanics to understanding
tissue mechanics. As one example of this direction,
single-molecule force spectroscopy on bone has re-
cently led to new insights into bone fracture mechanics
(Fantner et al., 2005). The hope is that a detailed under-
standing of tissue mechanics based on single-molecule
mechanics can contribute to a fuller understanding of
the molecules responsible for macroscopic phenomena
such as wound healing and tissue elasticity.
In general, atomic or molecular interactions involve
forces and energies. Energies can be measured by
bulk techniques and are very well-known for almost
any combination of atoms and a vast number of mo-
lecular interactions. Knowledge of interaction forces,
however, is much more difficult to obtain from bulk mea-
surements. This is one of the reasons that pulling with
the atomic force microscope to measure molecular me-
chanics has such a bright future.
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391A Tale of the Unexpected
A human homolog of the prokaryotic phosphate bind-
ing protein has been described and its structure deter-
mined (Morales et al., 2006 [this issue of Structure]).
This protein’s discovery in plasma was unexpected
and leads to questions as to what function this type
of protein might have in eukaryotes.
Research by its very nature leads us into the unex-
pected, but once in a while the twist in the tale provides
a reminder of this. When one protein is sought but an-
other found, fresh opportunities open up. In a paper in
this issue of Structure, Morales et al. (2006) describe
such a tale, the discovery and structural characteriza-
tion of a protein that is the first of its class in eukaryotes.
Chabriere and coworkers were investigating paraoxo-
nase (PON1), an enzyme responsible for inactivating
various organophosphorus compounds including insec-
ticides and nerve gasses. The fact that a human enzyme
is named after an insecticide, paraoxon, just shows that
all this is in relatively new territory. The true physiologi-
cal function of PON1 is apparently unknown, althoughit appears to have an important role in prevention of
atherosclerosis (Watson et al., 1995; Shih et al., 1998).
A hydrolase with such various activities is bound to
draw attention.
However, the research on this system took an unex-
pected turn when a novel protein was isolated by copuri-
fication with PON1 from human plasma. This discovery
led to a number of precise results, including a crystal
structure that shows that the new protein is closely re-
lated to the periplasmic phosphate binding protein
(PBP) of prokaryotes (Luecke and Quiocho, 1990).
Thus this human protein was designated HPBP, and it
shows a similar fold and binding site to the prokaryotic
protein, although there is limited sequence identity.
The described HPBP structure has a small oxyanion in
the binding site. It presumably binds inorganic phos-
phate (Pi) in the same way as the prokaryotic protein,
via the Venus fly trap model with the two domains en-
gulfing the Pi as they close the binding cleft via a
hinge-bend (and twist) (Brune et al., 1998, Mao et al.,
1982). In the case of Escherichia coli PBP, a structure
has also been obtained of a phosphate-free mutant
(Ledvina et al., 1998), which shows a significant opening
of the binding cleft. This mechanism produces a high
affinity and specificity for Pi, versus, for example,
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poprotein version of PBP from mycobacteria (Vyas
et al., 2003). In each case the phosphate binds tightly,
probably with a submicromolar dissociation constant.
In gram-negative bacteria, PBP and other similar li-
gand binding proteins are periplasmic and interact
with membrane bound ABC transporters to enable the
import of the cargo ligand. These proteins are generally
expressed when the organism is starved of the essential
small molecule, and are exported rapidly to the peri-
plasm. In the case of PBP, this process also includes
a phosphatase to liberate free Pi from soluble phosphate
esters. As such, PBP operates as part of a system to
scavenge limited phosphate and enable the ABC trans-
porter to import it, potentially against a concentration
gradient. In mycobacteria, the related ligand binding
proteins are membrane bound but possibly operate by
a similar mechanism.
So what is such a protein doing in eukaryotes, specif-
ically in human plasma? Unsurprisingly for a protein that
only came to light in this unexpected way, currently the
clues are limited.
From its sequence, HPBP belongs to a family of pro-
teins called DING that is widely distributed in eukary-
otes. The fact that the key amino acids in the phosphate
binding site are conserved in this family suggests that
this type of binding protein is widespread in eukaryotes;
it was previously suggested that members of this family
might be related to PBP (Kumar et al., 2004). The HPBP
is slightly larger than the archetypical PBP from E. coli. It
has several extra loops that may well be involved in its
distinct role. It tightly associates with PON1, which in
turn associates with high-density lipoprotein.
In the plasma itself, inorganic phosphate levels are
high enough to saturate HPBP, as its dissociation con-
stant is much less than the likely Pi concentration. In
this situation, only a protein with much weaker Pi binding
might be expected to be modulated between Pi-free and
Pi bound forms. As it is, exposed to the high Pi in plasma,
HPBP is always going to have Pi bound. One might not
think it necessary to have such a binding protein merely
to scavenge for Pi or more distinctly to help transport
this small molecule into compartments that otherwise
have limited Pi. At least in gram-negative bacteria, the
equivalent PBP is apparently not needed and so its ex-
pression is repressed when the Pi concentration in the
medium is high (Horiuchi et al., 1959, Medveczky and
Rosenberg, 1970, Yagil et al., 1976). Intriguingly Morales
et al. (2006) raise the possibility of a role in preventing
phosphate salt formation, specifically with calcium. An-
other DING protein has been implicated in prevention of
kidney stones by such a mechanism (Kumar et al., 2004).While PBPs in prokaryotes have a role in Pi import, pos-
sibly the direction in plasma may be reversed, helping
maintain compartments that are low in Pi.
The evidence that HPBP interacts tightly with PON1
gives rise to other possibilities. Does the interaction
with PON1 impinge directly on the function of each pro-
tein, for example by changing the enzyme specificity?
Alternatively, does the interaction form part of a complex
control mechanism, perhaps by modulating the affinity
of the HPBP or by directing it to particular locations?
Do the DING proteins actually interact with ABC trans-
porters? Structural and mechanistic studies on this pro-
tein and its interactions may well throw light on potential
functions. We can expect some interesting and fresh
directions in the future, which may identify a novel role
of the small molecule Pi and its binding proteins in
eukaryotes.
Martin R. Webb
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